Coherus’ Lucentis Biosimilar Outstrips Biogen Rival One Month After Launch

$100m In Cimerli Revenues Anticipated In 2023, Q Code Submitted

 
• By Dean Rudge
Iurii Kirsanov/Alamy Stock Photo
Coherus has raced ahead of the competition • Source: Shutterstock (Iurii Kirsanov / Alamy Stock Pho/Alamy Stock Photo)

More from Biosimilars

More from Products